New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 14, 2012
05:01 EDTHD, SAND, DVAX, EXEL, O, BRCM, CSCO, QCOM, BA, WPRT, GE, CLNE, GILD, CELG, DKS, SODAJim Cramer's "Mad Money"
Jim Cramer said there are plenty of reasons to still own stocks. As many are still hopeful for a deal that can avert the fiscal cliff. So why haven't stock prices cratered in the meantime? Cramer said there are many reasons. Many investors simply aren't aware of drastic consequences if a deal is not reached, while others have their investments in IRAs and other tax-favored accounts that may not be affected by the fiscal cliff. Those investors are buyers into weakness and help provide a cushion for the markets, Cramer said. Then there are the earnings, strong earnings, from the likes of Home Depot (HD) and Dicks Sporting Goods (DKS), which prove that Americans are still spending, especially on their homes. Other big moves, including from biotechs like Celgene (CELG) and Gilead Sciences (GILD), are hard to pass up, Cramer continued. In the end, being out of the market when a deal is reached would be a huge mistake, Cramer said, as even a bad outcome is better than no outcome at all. EXECUTIVE DECISION: Cramer once again sat down with Andrew Littlefair, CEO of Clean Energy Fuels (CLNE), a stock that's been cut in half since its highs earlier this year, but also one that received a boost Tuesday on the news that the company is building two liquefied natural gas plants with General Electric (GE). Littlefair said ultimately, Clean Energy plans 10 such plants, allowing the company to provide fuel along the major interstate corridors across our country. When Westport Innovations (WPRT) introduces the next-generation natural gas engines in February, Littlefair added, that will likely be the catalyst to convince many more truckers to begin using natural gas and start saving up to $1.50 per gallon in fuel costs. Cramer said Littlefair made him feel more upbeat on the prospects for natural gas in America. OFF THE CHARTS: Cramer and colleague Bob Lang went over the chart of Boeing (BA), one that is squarely in the crosshairs of the looming fiscal cliff. With a floor at $69 a share, Lang said investors have decent downside protection at these levels. More importantly, Boeing's recent rally now puts the stock above its 10-day, 50-day and 200-day moving averages, which makes it an "up stock" in the eyes of technicians who follow it. Cramer said there's a tremendous buying cycle at hand in the aerospace world, as more and more airlines need to add more fuel efficient planes to their fleets. This cycle lasts for years, he said, which is why Boeing is one stock that can fly higher than even the fiscal cliff. NO HUDDLE OFFENSE: Cramer took a moment out to praise the management at Home Depot and Dicks Sporting Goods for their remarkable earnings.Home Depot. LIGHTNING ROUND: (Bullish) QCOM; CSCO; BRCM; O; EXEL; DVAX. (Bearish) SAND; SODA.is now set to ride the waves of a recovering housing market and the rebuilding effort after Hurricane Sandy. Cramer said Dick's 5% pop in same store sales was remarkable during a time when many are not necessarily in the market for expensive sneakers or outdoor sporting gear. Reference Link
News For HD;DKS;CELG;GILD;CLNE;GE;WPRT;BA;QCOM;CSCO;BRCM;O;EXEL;DVAX;SAND;SODA From The Last 14 Days
Check below for free stories on HD;DKS;CELG;GILD;CLNE;GE;WPRT;BA;QCOM;CSCO;BRCM;O;EXEL;DVAX;SAND;SODA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>
July 10, 2014
06:28 EDTBAOptions expected to be active
Options expected to be active: LL PBPB VNO FDO WFC COST ZUMZ UAL BA
06:04 EDTCLNEClean Energy to double CNG statoin capacity for Saddle Creek gas station
Subscribe for More Information
05:45 EDTBABoeing forecasts demand for 36,770 new planes valued at $5.2T
Subscribe for More Information
July 9, 2014
18:50 EDTHDOn The Fly: After Hours Movers
Subscribe for More Information
18:09 EDTHDLumber Liquidators plummets after cutting full-year outlook
Shares of hardwood flooring and accessories retailer Lumber Liquidators (LL) are sinking in after-hours trading after the company cut its fiscal 2014 outlook. It also forecast second quarter results far below analysts' consensus estimates. WHAT'S NEW: After the bell, Lumber Liquidators forecast Q2 earnings per share of 59c-61c, far short of the consensus estimate of 90c. Q2 sales came in at $263.1M, also well below estimates of $303.21M. Comparable store sales decreased 7.1% for the quarter, and the company expects gross margin in Q2 to contract year over year. WHAT'S NOTABLE: Due to the weak Q2 performance, the company cut its FY14 EPS view to $2.65-$3.00 from $3.25-$3.60, versus consensus of $3.34. It also lowered its FY14 revenue outlook to $1.05B-$1.1B from $1.15B-$1.2B, versus consensus of $1.16B. It forecast comparable store net sales in the low single digits, either positive or negative, compared to its previous view of an increase ranging from mid to high single digits. It sees opening a total of 33 to 37 new store locations in the expanded showroom format, down from the previous view of 35 to 40. CEO Lynch said, "A number of the factors weighing on our second quarter results are likely to continue in the second half of 2014. While we believe the third quarter may be weaker than we originally anticipated, we have a strong sense of urgency and we expect to regain traction to deliver operating margin expansion in the second half and in coming years." PRICE ACTION: In evening trading, Lumber Liquidators fell $13.52, or 19.2%, to $56.90 on heavy trading volume. OTHERS TO WATCH: Other companies in the flooring space include Tile Shop (TTS), down 5%, Home Depot (HD), down 1%, and Lowe's (LOW), down 1.8%.
16:25 EDTCELGCelgene reports 11.9% passive stake in GlobeImmune
Subscribe for More Information
16:01 EDTGILDOptions Update; July 9, 2014
Subscribe for More Information
11:57 EDTCELGCelgene shares higher despite missing primary endpoint in Otezla trial
Subscribe for More Information
10:02 EDTBRCMOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:35 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AA FB AMZN TSLA TWTR MU NFLX GG CELG
09:13 EDTCELGOn The Fly: Pre-market Movers
Subscribe for More Information
07:33 EDTGILDGilead on track to post Q2 revenue beat, says RBC Capital
Subscribe for More Information
07:14 EDTCSCOTech Data announces U.S. distribution agreement with Cisco
Subscribe for More Information
07:06 EDTGEUniversal Stainless & Alloy achieves S-400, S-1000 approvals from GE Aviation
Subscribe for More Information
07:04 EDTCELGCelgene says OTEZLA did not achieve primary endpoint in Phase III trial
Celgene Corporation announced results of its phase III POSTURE study evaluating OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4, in patients with active ankylosing spondylitis. The OTEZLA arms did not achieve statistically significant improvement versus the placebo arm for the primary endpoint, the percentage of patients who achieve an ASAS 20 response at week 16. However, in a prespecified analysis, meaningful efficacy was observed at Week 24 in a large subset of patients with early-stage disease. Evaluation of the efficacy results is ongoing. An independent data monitoring committee recommended that the study proceed unchanged, based on an assessment of the safety and efficacy data at week 24. According to the protocol, magnetic resonance imaging data will be collected in a subgroup of subjects at week 52 and at additional time points, and radiographs will be taken on all study patients at week 104 and at additional time points. The safety and tolerability data observed in the POSTURE study are consistent with previously reported phase II data in ankylosing spondylitis, as well as six phase III studies of OTEZLA in psoriatic arthritis or psoriasis. No new safety signals were observed. The evaluation of safety and efficacy in the treatment arms is ongoing and the results of the study will be presented at an upcoming medical meeting. These results are from an investigational phase III study. OTEZLA is not approved for the treatment of patients with ankylosing spondylitis in any country.
06:51 EDTBABoeing expands maintenance support to customers in Southeast Asia
Subscribe for More Information
06:16 EDTQCOMQuclomm places FinFET chip orders with Samsung, DigiTimes reports
Subscribe for More Information
05:33 EDTBRCMBroadcom upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
05:24 EDTBABoeing, Emirates finalize order for 777Xs valued at $56B
Subscribe for More Information
05:10 EDTBABoeing, Air New Zealand announce first 787-9 Dreamliner delivery
Boeing announced the first 787-9 Dreamliner delivery with launch customer Air New Zealand. This 787-9, painted in a unique black livery, is the first of 10 Dreamliners to join Air New Zealand's fleet. The airline said the airplane will operate the Auckland–Perth route in October 2014 and to both Tokyo and Shanghai in November 2014.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use